Kilitch Drugs (India) Limited (KILITCH) - Net Assets
Based on the latest financial reports, Kilitch Drugs (India) Limited (KILITCH) has net assets worth Rs2.64 Billion INR (≈ $28.57 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.99 Billion ≈ $43.11 Million USD) and total liabilities (Rs1.34 Billion ≈ $14.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KILITCH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs2.64 Billion |
| % of Total Assets | 66.27% |
| Annual Growth Rate | 16.14% |
| 5-Year Change | 54.82% |
| 10-Year Change | 84.44% |
| Growth Volatility | 60.85 |
Kilitch Drugs (India) Limited - Net Assets Trend (2006–2025)
This chart illustrates how Kilitch Drugs (India) Limited's net assets have evolved over time, based on quarterly financial data. Also explore Kilitch Drugs (India) Limited balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Kilitch Drugs (India) Limited (2006–2025)
The table below shows the annual net assets of Kilitch Drugs (India) Limited from 2006 to 2025. For live valuation and market cap data, see KILITCH company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.00 Billion ≈ $21.68 Million |
+14.11% |
| 2024-03-31 | Rs1.76 Billion ≈ $19.00 Million |
+16.66% |
| 2023-03-31 | Rs1.51 Billion ≈ $16.28 Million |
+7.33% |
| 2022-03-31 | Rs1.40 Billion ≈ $15.17 Million |
+8.35% |
| 2021-03-31 | Rs1.29 Billion ≈ $14.00 Million |
+7.48% |
| 2020-03-31 | Rs1.20 Billion ≈ $13.03 Million |
-2.18% |
| 2019-03-31 | Rs1.23 Billion ≈ $13.32 Million |
+9.22% |
| 2018-03-31 | Rs1.13 Billion ≈ $12.19 Million |
+11.42% |
| 2017-03-31 | Rs1.01 Billion ≈ $10.94 Million |
-6.89% |
| 2016-03-31 | Rs1.09 Billion ≈ $11.75 Million |
-9.34% |
| 2015-03-31 | Rs1.20 Billion ≈ $12.96 Million |
-0.29% |
| 2014-03-31 | Rs1.20 Billion ≈ $13.00 Million |
+0.99% |
| 2013-03-31 | Rs1.19 Billion ≈ $12.88 Million |
+2.96% |
| 2012-03-31 | Rs1.16 Billion ≈ $12.50 Million |
+34.65% |
| 2011-03-31 | Rs858.72 Million ≈ $9.29 Million |
+15.91% |
| 2010-03-31 | Rs740.88 Million ≈ $8.01 Million |
+15.05% |
| 2009-03-31 | Rs643.97 Million ≈ $6.96 Million |
+25.49% |
| 2008-03-31 | Rs513.18 Million ≈ $5.55 Million |
+277.77% |
| 2007-03-31 | Rs135.84 Million ≈ $1.47 Million |
+16.37% |
| 2006-03-31 | Rs116.74 Million ≈ $1.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kilitch Drugs (India) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 126730800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs1.27 Billion | 62.64% |
| Common Stock | Rs160.82 Million | 7.95% |
| Other Comprehensive Income | Rs128.32 Million | 6.34% |
| Other Components | Rs466.84 Million | 23.07% |
| Total Equity | Rs2.02 Billion | 100.00% |
Kilitch Drugs (India) Limited Competitors by Market Cap
The table below lists competitors of Kilitch Drugs (India) Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nice D&B Co. Ltd
KQ:130580
|
$58.23 Million |
|
Montebalito S.A.
MC:MTB
|
$58.24 Million |
|
Changhong Meiling Co Ltd B
SHE:200521
|
$58.26 Million |
|
DocCheck AG
XETRA:AJ91
|
$58.35 Million |
|
Studio Mir Co. Ltd.
KQ:408900
|
$58.23 Million |
|
Microcosm Technology Co Ltd
TWO:3354
|
$58.20 Million |
|
Doxa AB
ST:DOXA
|
$58.17 Million |
|
Moberg Pharma AB (publ)
ST:MOB
|
$58.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kilitch Drugs (India) Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,762,912,000 to 2,023,291,000, a change of 260,379,000 (14.8%).
- Net income of 267,006,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 158,802,001.
- Other factors increased equity by 152,175,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs267.01 Million | +13.2% |
| Other Comprehensive Income | Rs-158.80 Million | -7.85% |
| Other Changes | Rs152.18 Million | +7.52% |
| Total Change | Rs- | 14.77% |
Book Value vs Market Value Analysis
This analysis compares Kilitch Drugs (India) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.74x to 2.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs8.68 | Rs154.02 | x |
| 2007-03-31 | Rs9.62 | Rs154.02 | x |
| 2008-03-31 | Rs19.44 | Rs154.02 | x |
| 2009-03-31 | Rs24.39 | Rs154.02 | x |
| 2010-03-31 | Rs27.44 | Rs154.02 | x |
| 2011-03-31 | Rs31.15 | Rs154.02 | x |
| 2012-03-31 | Rs42.80 | Rs154.02 | x |
| 2013-03-31 | Rs44.27 | Rs154.02 | x |
| 2014-03-31 | Rs45.43 | Rs154.02 | x |
| 2015-03-31 | Rs45.30 | Rs154.02 | x |
| 2016-03-31 | Rs41.07 | Rs154.02 | x |
| 2017-03-31 | Rs38.25 | Rs154.02 | x |
| 2018-03-31 | Rs39.78 | Rs154.02 | x |
| 2019-03-31 | Rs41.24 | Rs154.02 | x |
| 2020-03-31 | Rs38.34 | Rs154.02 | x |
| 2021-03-31 | Rs41.06 | Rs154.02 | x |
| 2022-03-31 | Rs44.68 | Rs154.02 | x |
| 2023-03-31 | Rs48.64 | Rs154.02 | x |
| 2024-03-31 | Rs55.36 | Rs154.02 | x |
| 2025-03-31 | Rs62.89 | Rs154.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kilitch Drugs (India) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.20%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.46%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.55x
- Recent ROE (13.20%) is above the historical average (8.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 3.66% | 1.75% | 0.55x | 3.79x | Rs-7.41 Million |
| 2007 | 7.40% | 3.10% | 0.46x | 5.18x | Rs-3.53 Million |
| 2008 | 22.06% | 9.66% | 0.89x | 2.56x | Rs61.89 Million |
| 2009 | 17.30% | 8.64% | 0.90x | 2.22x | Rs47.04 Million |
| 2010 | 13.81% | 7.17% | 1.03x | 1.87x | Rs28.23 Million |
| 2011 | 12.44% | 7.17% | 0.91x | 1.91x | Rs20.57 Million |
| 2012 | 66.62% | 70.68% | 0.61x | 1.54x | Rs648.56 Million |
| 2013 | 2.76% | 9.89% | 0.24x | 1.15x | Rs-86.22 Million |
| 2014 | 0.98% | 7.90% | 0.12x | 1.07x | Rs-108.46 Million |
| 2015 | -0.24% | -1.52% | 0.15x | 1.06x | Rs-122.77 Million |
| 2016 | -10.30% | -53.33% | 0.18x | 1.07x | Rs-220.60 Million |
| 2017 | -8.78% | -32.73% | 0.24x | 1.12x | Rs-190.10 Million |
| 2018 | 4.60% | 10.10% | 0.40x | 1.14x | Rs-60.50 Million |
| 2019 | 3.16% | 4.64% | 0.57x | 1.19x | Rs-82.76 Million |
| 2020 | 0.71% | 1.58% | 0.37x | 1.21x | Rs-109.83 Million |
| 2021 | 2.89% | 5.39% | 0.34x | 1.60x | Rs-90.42 Million |
| 2022 | 5.30% | 6.45% | 0.54x | 1.51x | Rs-65.41 Million |
| 2023 | 6.89% | 7.48% | 0.64x | 1.45x | Rs-47.12 Million |
| 2024 | 8.28% | 9.51% | 0.64x | 1.36x | Rs-30.28 Million |
| 2025 | 13.20% | 13.46% | 0.63x | 1.55x | Rs64.68 Million |
Industry Comparison
This section compares Kilitch Drugs (India) Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kilitch Drugs (India) Limited (KILITCH) | Rs2.64 Billion | 3.66% | 0.51x | $58.23 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more